Seelos Therapeutics, Inc. (OTCPK: SEEL.Q)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Seelos Therapeutics, Inc. (OTCPK: SEEL.Q) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $136.00 and employs 8 people.
trading between 0.00 and 0.01.
Tweenvest scores Seelos Therapeutics, Inc. across four factors: quality 6/100, value 45/100. Its strongest factor is value.
SEEL.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $136.00
- Revenue (TTM)
- $2.01M
- P/E
- 0.00
- EPS
- 47.06
- Dividend yield
- —
- Beta (5Y)
- 7.21
- 52-week high
- $0.01
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.36M
- Employees
- 8
- Next earnings
- —
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
- ISIN
- US81577F4063
- Founded
- 2016
- Listed since
- Apr 19, 1999
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,262.50 | +0.57% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.94 | +0.63% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | 0.00% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.90 | -1.52% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.80 | -1.31% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.